Nanostructured Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ for nanomedicine: catalytic degradation of DNA in cancer cells

Tessy López$^{1,2,3}$, Emma Ortíz Islas$^2$, Mayra A. Alvarez Lemus$^2$* and Richard Donald González$^3$

$^1$Health Department, Universidad Autónoma Metropolitana-Xochimilco, México City, México; $^2$Nanotechnology Laboratory, National Institute of Neurology and Neurosurgery, México City, México; $^3$Department of Chemical and Biomolecular Engineering, Tulane University, New Orleans, LA, USA

Received: 12 July 2010; Revised: 18 November 2010; Accepted: 2 December 2010; Published: 13 January 2011

Abstract

In vivo suppression of glioblastoma multiforme (GBM) in Wistar rats using silica-shelled biocatalytic Pt(NH$_3$)$_4$Cl$_2$ nanoparticles is reported. These nanoparticles were synthesized by a sol-gel technique and characterized by SEM and HRTEM imaging. We confirmed morphological uniformity (30 nm) and surface acidity of the nanoparticles, respectively, by TEM imaging and FTIR spectral analysis. Interestingly, treatment of Wistar rats intraperitoneally inoculated with C$_6$ cells using the biocatalysts resulted in considerable tumor shrinkage. Efficiency of the biocatalyst to shrink a tumor is superior to that by the commercial cytotoxic agent cisplatin. The tumor suppression property of Pt(NH$_3$)$_4$Cl$_2$ nanoparticles is attributed to catalytic damage of DNA in C$_6$ cells.

Keywords: nanotechnology; nanomedicine; local delivery; GBM; Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$; sol-gel silica

Controlled drug delivery to the brain date back to the 1970s, when Chisholm and Singer (1) used a cannula to release fluids directly into the central nervous system (CNS) of rats without any perceptible harm to the animal. These studies generated great interest in the administration of drugs with microinjections in specific areas (2–5). Recently, the use of nanoparticles for cancer treatment has attracted much attention, mainly in the drug delivery (6) and photodynamic therapy fields (7). Doxorubicine, BCNU (8), methotrexate, and 5-FU are chemotherapeutic agents that are extensively encapsulated in a great variety of nanoparticles.

Due to the blood brain barrier (BBB), only a small number of chemotherapeutic agents are suitable for the treatment of brain tumors (9). Currently Temozolomide is the best well-tolerated drug that can cross BBB (10–13). In the case of malignant tumors like glioblastoma multiforme (GBM) (13–16), Temozolomide can improve life expectancy by 6 months. Because GBM spreads very rapidly and infiltrates healthy tissue, complete resection is practically impossible, leaving the survival index of patients with GBM rather low even after surgery, radiotherapy, and chemotherapy.

Due to its well-known DNA reactivity, cisplatin exhibits high antitumoral activity and is one of the most widely accepted chemotherapeutic agent in the treatment of several cancers. However, some recent reports show that only cis-conformations of platinum complexes are effective against cancer (17, 18). Here we report in vivo suppression of GBM in Wistar rats treated with silica-shelled tetraminedichloro platinum(II) nanoparticles. These nanoparticles were prepared by incorporating tetraminedichloro platinum(II) in silica shells by a sol-gel process. We investigated relations among acidic sites on the nanoparticles, in vivo interactions between Pt-supported nanoparticles and DNA in C$_6$ cells, and tumor suppression.

Nano Reviews 2011. © 2011 T. López et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Nano Reviews 2011, 2:5461 - DOI: 10.3402/nano.v2i0.5461
Results and discussion

We examined the morphology and structure of Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ nanoparticles by SEM and TEM imaging and energy dispersive spectroscopy (EDS). A typical SEM image of Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ nanoparticles is shown in Fig. 1a. Morphology of the material indicates agglomeration of small particles into non-uniform nanostructures. High resolution TEM image provided us with evidence for 1 nm diameter Pt(NH$_3$)$_4$Cl$_2$ complexes embedded in silica shells (Fig. 1c). These nanoparticles were further characterized by an EDS analysis, which indicates the presence of silicon, oxygen, platinum, and chlorine (supplementary information).

We investigated in vivo suppression of C$_6$ tumor in a Wistar rat using the biocatalytic Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ nanoparticles. At first, C$_6$ cells (obtained from the American Tissue Culture Collection, Rockville, MD) were cultured into sufficient quantity and, subsequently, 1x10$^7$ C$_6$ cells were intraperitoneally inoculated in a Wistar strain male rat in order to develop a GBM type tumor. Twenty days after inoculation the C$_6$ tumor had grown to an acceptable size in 80% of the animals (19). When the rats developed a tumor of 2 cm, they were randomly allocated into four groups as follows: (A) control (no administration), (B) administered with a suspension of the Pt complex, (C) administered with a suspension of sol-gel silica nanoparticles, and (D) administered with a suspension of Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ nanoparticles. Twenty-one days after the administration of these nanoparticles, tumors were surgically extracted and analyzed ex vivo. Also, we examined the effect of in vivo administered nanoparticles on tumor size. We found that suppression of the tumor was negligible in the group of rats administered with the Pt complex or sol-gel silica nanoparticles. On the other hand, a decrease in the tumor size (approximately a 73% reduction) was significant in the group of rats administered with sol-gel Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ nanoparticles. We attribute that the tumor suppression activity of sol-gel Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ nanoparticles comes from killing of cancer cells via free radicals inducing DNA damage. These possibilities investigated by ex vivo analysis of tumor sections and ex vivo and in vitro analyses of DNA damage in C$_6$ cancer cells.

The H-E micrographs of histological sections from tumors after treatment with Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ nanoparticles are shown in Fig. 2. We analyzed different tumor regions at low and high magnifications. Histological studies were conducted following the path of injection to associate direct action of nanoparticles with tumor suppression. Fig. 2b shows the area in H-E stained sections from the C$_6$ tumor with viable tumor cells where inducing cell death via DNA damage. These possibilities were investigated by ex vivo analysis of tumor sections and ex vivo and in vitro analyses of DNA damage in C$_6$ cancer cells.

Fig. 2. H-E stained sections from the C$_6$ tumor in a Wistar rat treated with Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$. (a–c) Low magnification and (d–h) high magnification.
characteristic GBM cells morphology can be identified. In Fig. 2d, two different zones are observed: the upper region consists more of viable tumor cells; whereas, cell damage is remarkable in the lower region. The tumor suppression by Pt(NH\textsubscript{3})\textsubscript{4}Cl\textsubscript{2}/SiO\textsubscript{2} nanoparticles is clearly presented at a higher magnification in Fig. 2h, which is indicative of a chemotherapeutic effect of the nanoparticles. On the other hand, we could not identify any remarkable changes to tumors in control animals (group A–C).

The in vivo effect of Pt(NH\textsubscript{3})\textsubscript{4}Cl\textsubscript{2}/SiO\textsubscript{2} nanoparticles on the C\textsubscript{6} tumor was examined by the cell viability assay of an extracted tumor using Trypan blue. In this assay, live cells exclude Trypan blue dye by retarding its intracellular diffusion; whereas, the dye effectively enters inside dead cells because of their poor cell wall integrity. Fig. 3 shows histological images of a C\textsubscript{6} tumor in vivo treated with Pt(NH\textsubscript{3})\textsubscript{4}Cl\textsubscript{2}/SiO\textsubscript{2} nanoparticles. Remarkable intensity of the stain is indicative of anticancer activity of the nanoparticles. Dead cells in the C\textsubscript{6} tumor are clearly identified in images at higher magnification (Fig. 3c–h).

We assume that the anticancer activity of Pt(NH\textsubscript{3})\textsubscript{4}Cl\textsubscript{2}/SiO\textsubscript{2} nanoparticles originates as a result of intracellular uptake of the nanoparticles, interactions of the nanoparticles with genetic materials, and subsequent damage of DNA.

We examined DNA damage for C\textsubscript{6} cells in tumors treated with the biocatalytic nanoparticles by analyzing terminal transferase (TUNEL assay). In the TUNEL assay, end labeling techniques are employed for studying the actual mechanism of DNA fragmentation, as well as the detection and characterization of endonucleases. Endonucleases cleave DNA by attacking the phosphodiester bonds of the sugar–phosphate backbone of each strand. The phosphodiester bond can be cleaved in two ways such that the phosphate is left on either the 3’ end of the DNA strand or the 5’ end, the opposite end being left with a hydroxyl group in each case. The TUNEL image of a C\textsubscript{6} tumor is shown in Fig. 4. The white dots observed in

![Figure 3](image3.png) **Fig. 3.** Trypan blue histological images of sections from C\textsubscript{6} tumors in Wistar rats treated with Pt(NH\textsubscript{3})\textsubscript{4}Cl\textsubscript{2}/SiO\textsubscript{2} nanoparticles. (a–c) Low magnification and (d–h) high magnification.

![Figure 4](image4.png) **Fig. 4.** Representative TUNEL images from a C\textsubscript{6} tumor: (a) Tumor treated using Pt(NH\textsubscript{3})\textsubscript{4}Cl\textsubscript{2}/SiO\textsubscript{2} and (b–c) higher magnification.
Fig. 4 represent fluorescent ends of fragmented DNA. The TUNEL technique is widely used to quantify apoptotic cells, because it allows identifying affected cells. This technique detects DNA fragmentation by endogenous DNA, the final step in apoptosis. In order to identify the cell death process (apoptosis or necrosis), a specific fluorescent enzyme is used to mark the ends of the fragmented DNA. This is characteristic of cell death by apoptosis (programmed cell death), instead of necrosis in which the membrane collapses and cells are rapidly destroyed. Therefore, the white dots in Fig. 4 is indicative of DNA fragmentation in tumors treated with Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ nanoparticles. The effect of Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ nanoparticles on DNA damage and fragmentation was confirmed from in vitro treatment of C6 cells with the nanoparticles (supplementary information).

In summary, we developed a new biocatalytic nanoparticle for the treatment of tumors. Wistar rats intraperitoneally inoculated with C6 cancer cells and treated with the biocatalyst resulted in nearly 73% shrinkage of the tumor. The tumor suppression is due to the killing of cancer cells via intracellular uptake and DNA fragmentation. The small dimension of the SiO$_2$ particles along with Pt(NH$_3$)$_4$Cl$_2$ enable intracellular uptake of the nanoparticles. Also, the uniform porous nature of supported Pt(NH$_3$)$_4$Cl$_2$/SiO$_2$ with small particle size (1–2 nm) is likely the prerequisite for an efficient catalytic degradation of DNA in cancer cells. These results suggest that administration of chemotherapeutic nanoparticles can be an effective treatment for aggressive tumors such as GBM. We firmly believe that a new chapter in catalytic nanomedicine has been opened in the chemotherapeutic treatment of malignant tumors through the use of biocatalytic nanoparticles.

Acknowledgements

The authors gratefully acknowledge financial support from CONACYT-FONCICYT project 96095, the National Institute of Neurology and Neurosurgery (México) and Autonomous Metropolitan University. The authors gratefully acknowledge to P. Arteaga, J. Navarrete, J. Uddin, and J. Bustos for technical assistance. We especially thank Dr. Ulrike Diebold (Tulane University) for her fruitful discussion.

Conflict of interest and funding

There is no conflict of interest in the present study for any of the authors.

References

1. Chisholm B, Singer G. A new type of cannula for central administration of drugs in rats. Physiol Behav 1970; 5: 1069–70.
2. Covian MR, Gentil CG, Antunes-Rodrigues J. Water and sodium chloride intake following microinjections of angiotensin II into the septal area of the rat brain. Physiol Behav 1972; 9: 373–6.
3. Broekkamp CL, Van Den Bogaard JH, Heijnen HJ, Rops RH, Cools AR, Rossum MV. Separation of inhibiting and stimulating effects of morphine on self-stimulation behavior by intracerebral microinjections. Eur J Pharmacol 1976; 36: 443–6.
4. Ervin GN, Fink JS, Young RC, Smith GP. Different behavioral responses to L-DOPA after anterolateral or posterolateral hypothalamic injections of 6-hydroxydopamine. Brain Res 1977; 132: 507–20.
5. Gutman RL, Peacock G, Lu DR. Targeted drug delivery for brain cancer treatment. J Control Rel 2000; 65: 31–41.
6. Janes KA, Fresnau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Rel 2001; 73: 255–67.
7. Allison RR, Mota HC, Bagnato VS, Sibata CH. Biosynthetic nanoparticles and photodynamic therapy – state of the art review. Photodiag Photodynam Ther 2008; 5: 19–28.
8. Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992; 76: 640–7.
9. Wang PP, Frazier J, Brem H. Local drug delivery to the brain. Adv Drug Deliv Rev 2002; 54: 987–1013.
10. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Cochrane Database of Systematic Reviews (Online) [Cochrane Database Syst Rev]. ISSN: 1469-493X, 2008.
11. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006; 32: 74–89.
12. Van Nifterik KA, Van den Berg J, Stalpers LJA, Lafleur MVM, Leenstra S, Slotman BJ, et al. Differential radiosensitizing potential of temozolomide in mgmt promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 2007; 69: 1246–53.
13. CBTRUS. Statistical report: primary brain tumors in the United States, 1998–2002 (Central Brain Tumor Registry of the United States, 2008).
14. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy and The National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–96.
15. Plowman PN, Kingston JE, Sebag-Montefiore D, Doughty D. Clinical efficacy of perceived ‘CNS friendly’ chemoradiotherapy for primary intracranial germ cell tumours. Clin Oncol 1997; 9: 48–53.
16. Bauman GS, Sneed PK, Wara WM, Stalpers LJA, Chang SM, Medermott MW, et al. Reirradiation of CNS primary tumors. Int J Radiat Oncol Biol Phys 1996; 36: 433–41.
17. Gonzalez-Vadillo AM, Alvarez-Valdes A, Moneo V, Blanco F, Diaz RG, Carnero A, et al. Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death. J Inorg Biochem 2007; 101: 551-8.

18. Ranconi L, Sadler PJ. Using coordination chemistry to design new medicines. Coord Chem Rev 2007; 251: 1633-48.

19. Arrieta O, Guevara P, Escobar E, Garcia-Navarrete R, Pineda B, Sotelo J. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Brit J Cancer 2005; 92: 1247-52.

*Mayra A. Alvarez*
Nanotechnology Laboratory
National Institute of Neurology and Neurosurgery
Insurgentes 3877, México DF 14279
México
Tel: +52 55 56063822 ext 5034
Fax: +52 55 5528806
Email: maalvarez@innn.edu.mx